Core Viewpoint - Appili Therapeutics has secured new patents for its oral formulation of metronidazole, LIKMEZ, enhancing its market protection and supporting its commercialization efforts [1][2][3] Patent Protection - The newly granted patents will expire in 2039 and provide comprehensive protection for LIKMEZ, covering its unique taste-masked composition and therapeutic applications [2] - The U.S. patent has been listed in the FDA's Orange Book, which is crucial for ensuring additional protection for the formulation [2][3] Product Overview - LIKMEZ is the first FDA-approved ready-made suspension of metronidazole, specifically designed for treating antimicrobial-resistant infections, particularly beneficial for patients with dysphagia [4] - The formulation aims to improve stability and palatability, which are essential for patient adherence to medication and better treatment outcomes [3] Commercialization Efforts - Saptalis Pharmaceuticals, the partner of Appili, is planning to re-launch LIKMEZ under its own label in May 2025, leveraging the newly granted patent for commercialization activities [3][4] - The collaboration with Saptalis emphasizes the commitment to bringing innovative pharmaceutical solutions to market [5][6] Company Background - Appili Therapeutics focuses on developing therapies for infectious diseases and aims to address urgent medical needs through a diverse pipeline of anti-infectives [7][9] - The company is strategically positioned to tackle life-threatening infections, with a proven management team leading its initiatives [9]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Exhibit 99.1 Current cloud backlog of €18.2 billion, up 28% and up 29% at constant currencies Cloud revenue up 27% and up 26% at constant currencies Cloud ERP Suite revenue up 34% and up 33% at constant currencies Total revenue up 12% and up 11% at constant currencies IFRS operating profit of €2.3 billion; non-IFRS operating profit of €2.5 billion, up 60% and up 58% at constant currencies | Q1 2025 in € millions, unless otherwise stated | | --- | | Current cloud | Total revenue | Cloud & | Cloud revenue | | ...

Group 1 - The core viewpoint is that SAP is expected to continue delivering solid earnings growth, particularly through its successful execution of cloud strategies [1] - The investment approach emphasizes a fundamentals-based strategy, focusing on companies with long-term durability and robust balance sheets rather than merely low multiples [1] - There is a recognition that investing in successful companies carries risks, particularly regarding valuation, but vast development opportunities can lessen the immediate importance of price [1]

Chesapeake Utilities Corporation (NYSE: CPK ) is a regulated natural gas utility that operates in the states of Delaware, Maryland, and Florida. The company also operates as a natural gas-focused midstream company in the states of Delaware, Maryland, Pennsylvania, Florida, andAt Energy Profits in Dividends, we seek to generate a 7%+ income yield by investing in a portfolio of energy stocks while minimizing our risk of principal loss. By subscribing, you will get access to our best ideas earlier than they ar ...

I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve around is momentum.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within th ...

Core Viewpoint - Scienture Holdings, Inc. is preparing for the commercial launch of Arbli, a novel oral liquid formulation of losartan, aimed at addressing unmet needs in the hypertension treatment market, with a targeted launch date in July 2025 [1][5]. Company Overview - Scienture Holdings, Inc. operates as a holding company for pharmaceutical companies focused on developing and distributing specialty products that enhance value for patients and healthcare providers [1][12]. - Scienture, LLC, a wholly owned subsidiary, is responsible for the manufacturing and distribution of Arbli [1][12]. Product Details - Arbli is the first FDA-approved ready-to-use oral liquid formulation of losartan in the U.S., designed for patients over 6 years old, particularly for hypertension and related conditions [2][4]. - The product is available in a 165 mL bottle with a peppermint flavor, has a shelf life of 18 months at room temperature, and does not require refrigeration [6]. Market Context - Losartan, classified as an angiotensin receptor blocker (ARB), is one of the most prescribed medications for hypertension, with annual sales of approximately $292 million and a prescription volume of 68 million in the U.S. market as of December 2024 [4]. - Arbli addresses the limitations of existing losartan products, which are only available in solid forms that require compounding for liquid formulations, thus providing a safer and more convenient option for patients [3][4]. Manufacturing and Distribution - Scienture, LLC has initiated supply chain activities and partnered with Saptalis Pharmaceuticals for the manufacturing of Arbli, ensuring readiness for the planned launch [1][5]. - The company has also established agreements with strategic partners for warehousing and distribution to various wholesalers [1].

Core Insights - Sapiens International (SPNS) has demonstrated resilience in 2025, with shares down only 2.3% year to date, outperforming the broader Zacks Computer & Technology sector's decline of 14% [1] - The company's consistent recurring revenues, expanding clientele, and strong partner base, including Microsoft and Cognizant, have contributed to its relative strength [1] Revenue Performance - In 2024, recurring and reoccurring revenues from software products and post-production services increased by 14.1% compared to 2023, reaching $390 million, which accounted for 72% of total revenues [2] Product and Service Innovations - Sapiens has launched StatementPro Multi-Company Operations, allowing customers to streamline statutory reporting across multiple statements and companies, thereby reducing administrative burdens and increasing productivity [3] - The latest releases of Sapiens IllustrationPro and Sapiens ApplicationPro enhance automation, risk intelligence, and operational efficiency for agents and advisors [3] Competitive Positioning - Sapiens has outperformed peers like Clearwater Analytics, whose shares have dropped 15.8% year to date [4] - Clearwater's platform aggregates data on over $8.8 trillion of global invested assets for more than 1,400 clients as of December 31, 2024 [4] Strategic Partnerships - Sapiens has successfully expanded its System Integrator ecosystem, strengthening partnerships with Deloitte and LTIMindtree, and establishing new collaborations with Coforge and Cognizant [5] - The partnership with Microsoft is crucial for driving product innovation in the insurance industry, with Sapiens' SaaS solution now available in the Microsoft Azure marketplace [6] Client Acquisitions - Universal Life, a major life and health insurer in Cyprus, has selected Sapiens CoreSuite for Life & Pensions to modernize its core insurance systems, aiming to replace legacy systems and enhance operational performance [7] - Hiscox UK has successfully implemented the Sapiens Insurance Platform, achieving a 30% improvement in application speed and better integration capabilities [8] - Pioneer Insurance and Surety Corporation in the Philippines has chosen the Sapiens Insurance Platform to further its digital transformation, expanding Sapiens' international presence [9] Financial Guidance - For fiscal 2025, Sapiens projects revenues between $553 million and $558 million, with the Zacks Consensus Estimate at $555.81 million, indicating a 2.48% increase from the prior year [10] - The Zacks Consensus Estimate for earnings is $1.46 per share, reflecting a year-over-year decline of 1.35% [10] - The first-quarter 2025 revenue estimate is $136.51 million, suggesting a 1.69% increase from the prior year, while the earnings estimate is 35 cents per share, indicating a year-over-year decline of 2.78% [11]

ROCHELLE PARK, N.J., April 17, 2025 /PRNewswire/ -- Sapiens International Corporation (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, announced today that it will report its financial results for the First quarter of 2025 on Thursday, May 8, 2025.Management will host a conference call and webcast on May 8, 2025, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens' results. Please call the following numbers (at least 10 minute ...

New release streamlines NAIC filings and boosts productivity ROCHELLE PARK, N.J., April 8, 2025 /PRNewswire/ -- Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced the release of StatementPro Multi-Company Operations (MCO). This powerful new feature set, available to all Sapiens Financial & Compliance (F&C) customers, enables insurers to streamline statutory reporting by performing the same actions across ...